SCOPUS 정보 검색 플랫폼

Medicinal Research Reviews

Volumn 33, Issue 6, 2013, Pages 1278-1303

The acyclic nucleoside phosphonates (ANPs): Antonín holý's legacy

(1) De Clercq, Erik a

a REGA INSTITUTE FOR MEDICAL RESEARCH (Belgium)

Author keywords

Cidofovir; HIV; Nucleoside phosphonates; Tenofovir; Truvada

Indexed keywords

9 (2,3 DIHYDROXYPROPYL)ADENINE; 9 (3 FLUORO 2 PHOSPHONOMETHOXYPROPYL)ADENINE; 9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; ACICLOVIR; ACYCLIC NUCLEOSIDE PHOSPHONIC ACID DERIVATIVE; ADEFOVIR; ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; ATAZANAVIR; AZACITIDINE; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; COBICISTAT; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; DARUNAVIR; DUVIRAGEL; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELVITEGRAVIR; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GS 9191; GS 9219; NUCLEOSIDE DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; PLACEBO; TENOFOVIR; TENOFOVIR 3 HEXADECYLOXYPROPYL ESTER; TENOFOVIR ALAFENAMIDE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; NUCLEOSIDE;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; BRASSICA; CAULIFLOWER MOSAIC VIRUS; COMPARATIVE STUDY; CONDYLOMA ACUMINATUM; CONTAGIOUS ECTHYMA; CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS RETINITIS; DNA VIRUS; FOOD AND DRUG ADMINISTRATION; HEPATITIS B; HERPES LABIALIS; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; MOLLUSCUM CONTAGIOSUM; MONKEYPOX; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; PAPILLOMAVIRUS INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PLANT VIRUS; PLASMODIUM FALCIPARUM; POLYOMAVIRUS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; TABLET; TREATMENT DURATION; VIRUS STRAIN; CHEMISTRY; DRUG EFFECTS;

ANTIVIRAL AGENTS; HUMANS; NUCLEOSIDES; ORGANOPHOSPHONATES; PLANT VIRUSES;

EID: 84884989191 PISSN: 01986325 EISSN: 10981128 Source Type: Journal
DOI: 10.1002/med.21283 Document Type: Article

Times cited : (62)

References (99)

1
- 0017072864
- Adenine arabinoside therapy of herpes zoster in the immunosuppressed. NIAID collaborative antiviral study
- Whitley RJ, Ch'ien LT, Dolin R, Galasso GJ, Alford CA, Jr. Adenine arabinoside therapy of herpes zoster in the immunosuppressed. NIAID collaborative antiviral study. N Engl J Med 1976;294:1193-1199.
- (1976) N Engl J Med , vol.294 , pp. 1193-1199
- Whitley, R.J.¹ Ch'ien, L.T.² Dolin, R.³ Galasso, G.J.⁴ Alford Jr, C.A.⁵

2
- 0018090383
- (S)-9-(2,3-dihydroxypropyl)adenine: An aliphatic nucleoside analog with broad-spectrum antiviral activity
- De Clercq E, Descamps J, De Somer P, Holý A. (S)-9-(2, 3-dihydroxypropyl)adenine: An aliphatic nucleoside analog with broad-spectrum antiviral activity. Science 1978;200:563-565.
- (1978) Science , vol.200 , pp. 563-565
- De Clercq, E.¹ Descamps, J.² De Somer, P.³ Holý, A.⁴

3
- 0017639148
- Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine
- Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. Proc Natl Acad Sci USA 1977;74:5716-5720.
- (1977) Proc Natl Acad Sci USA , vol.74 , pp. 5716-5720
- Elion, G.B.¹ Furman, P.A.² Fyfe, J.A.³ de Miranda, P.⁴ Beauchamp, L.⁵ Schaeffer, H.J.⁶

4
- 0017811137
- 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group
- Schaeffer HJ, Beauchamp L, de Miranda P, Elion GB, Bauer DJ, Collins P. 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature 1978;272:583-585.
- (1978) Nature , vol.272 , pp. 583-585
- Schaeffer, H.J.¹ Beauchamp, L.² de Miranda, P.³ Elion, G.B.⁴ Bauer, D.J.⁵ Collins, P.⁶

5
- 33747123642
- Antiviral acyclic nucleoside phosphonates structure activity studies
- Holý A. Antiviral acyclic nucleoside phosphonates structure activity studies. Antiviral Res 2006;71:248-253.
- (2006) Antiviral Res , vol.71 , pp. 248-253
- Holý, A.¹

6
- 0022450584
- A novel selective broad-spectrum anti-DNA virus agent
- De Clercq E, Holý A, Rosenberg I, Sakuma T, Balzarini J, Maudgal PC. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986;323:464-467.
- (1986) Nature , vol.323 , pp. 464-467
- De Clercq, E.¹ Holý, A.² Rosenberg, I.³ Sakuma, T.⁴ Balzarini, J.⁵ Maudgal, P.C.⁶

7
- 57349120749
- The discovery of antiviral agents: Ten different compounds, ten different stories
- De Clercq E. The discovery of antiviral agents: Ten different compounds, ten different stories. Med Res Rev 2008;28:929-953.
- (2008) Med Res Rev , vol.28 , pp. 929-953
- De Clercq, E.¹

8
- 0023607245
- Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines
- De Clercq E, Sakuma T, Baba M, Pauwels R, Balzarini J, Rosenberg I, Holý A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res 1987;8:261-272.
- (1987) Antiviral Res , vol.8 , pp. 261-272
- De Clercq, E.¹ Sakuma, T.² Baba, M.³ Pauwels, R.⁴ Balzarini, J.⁵ Rosenberg, I.⁶ Holý, A.⁷

9
- 0002734366
- Therapeutic potential of HPMPC as an antiviral drug
- De Clercq E. Therapeutic potential of HPMPC as an antiviral drug. Rev Med Virol 1993;3:85-96.
- (1993) Rev Med Virol , vol.3 , pp. 85-96
- De Clercq, E.¹

10
- 4444256678
- Antivirals and antiviral strategies
- De Clercq E. Antivirals and antiviral strategies. Nat Rev Microbiol 2004;2:704-720.
- (2004) Nat Rev Microbiol , vol.2 , pp. 704-720
- De Clercq, E.¹

11
- 77953381888
- Yet another ten stories on antiviral drug discovery (part D): Paradigms, paradoxes, and paraductions
- De Clercq E. Yet another ten stories on antiviral drug discovery (part D): Paradigms, paradoxes, and paraductions. Med Res Rev 2010;30:667-707.
- (2010) Med Res Rev , vol.30 , pp. 667-707
- De Clercq, E.¹

12
- 78650003024
- The next ten stories on antiviral drug discovery (part E): Advents, advances, and adventures
- De Clercq E. The next ten stories on antiviral drug discovery (part E): Advents, advances, and adventures. Med Res Rev 2011;31:118-160.
- (2011) Med Res Rev , vol.31 , pp. 118-160
- De Clercq, E.¹

13
- 0035997915
- Cidofovir in the treatment of poxvirus infections
- De Clercq E. Cidofovir in the treatment of poxvirus infections. Antiviral Res 2002;55:1-13.
- (2002) Antiviral Res , vol.55 , pp. 1-13
- De Clercq, E.¹

14
- 32544444895
- Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection
- Stittelaar KJ, Neyts J, Naesens L, van Amerongen G, van Lavieren RF, Holý A, De Clercq E, Niesters HG, Fries E, Maas C, Mulder PG, van der Zeijst BA, Osterhaus AD. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature 2006;439:745-748.
- (2006) Nature , vol.439 , pp. 745-748
- Stittelaar, K.J.¹ Neyts, J.² Naesens, L.³ van Amerongen, G.⁴ van Lavieren, R.F.⁵ Holý, A.⁶ De Clercq, E.⁷ Niesters, H.G.⁸ Fries, E.⁹ Maas, C.¹⁰ Mulder, P.G.¹¹ van der Zeijst, B.A.¹² Osterhaus, A.D.¹³

15
- 67649744221
- Antiviral drug discovery: Ten more compounds, and ten more stories (part B)
- De Clercq E. Antiviral drug discovery: Ten more compounds, and ten more stories (part B). Med Res Rev 2009;29:571-610.
- (2009) Med Res Rev , vol.29 , pp. 571-610
- De Clercq, E.¹

16
- 67649744219
- Another ten stories in antiviral drug discovery (part C): "Old" and "new" antivirals, strategies, and perspectives
- De Clercq E. Another ten stories in antiviral drug discovery (part C): "Old" and "new" antivirals, strategies, and perspectives. Med Res Rev 2009;29:611-645.
- (2009) Med Res Rev , vol.29 , pp. 611-645
- De Clercq, E.¹

17
- 84874107763
- Highlights in antiviral drug research: antivirals at the horizon
- De Clercq E. Highlights in antiviral drug research: antivirals at the horizon. Med Res Rev 2013;33:1215-1248.
- (2013) Med Res Rev , vol.33 , pp. 1215-1248
- De Clercq, E.¹

18
- 84884974017
- A cutting edge view on the current state of antiviral drug development
- De Clercq E. A cutting edge view on the current state of antiviral drug development. Med Res Rev 2013;33:1249-1277.
- (2013) Med Res Rev , vol.33 , pp. 1249-1277
- De Clercq, E.¹

19
- 0023741036
- Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents
- Pauwels R, Balzarini J, Schols D, Baba M, Desmyter J, Rosenberg I, Holý A, De Clercq E. Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob Agents Chemother 1988;32:1025-1030.
- (1988) Antimicrob Agents Chemother , vol.32 , pp. 1025-1030
- Pauwels, R.¹ Balzarini, J.² Schols, D.³ Baba, M.⁴ Desmyter, J.⁵ Rosenberg, I.⁶ Holý, A.⁷ De Clercq, E.⁸

20
- 0003303887
- Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent
- Balzarini J, Naesens L, Herdewijn P, Rosenberg I, Holý A, Pauwels R, Baba M, Johns DG, De Clercq E. Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proc Natl Acad Sci USA 1989;86:332-336.
- (1989) Proc Natl Acad Sci USA , vol.86 , pp. 332-336
- Balzarini, J.¹ Naesens, L.² Herdewijn, P.³ Rosenberg, I.⁴ Holý, A.⁵ Pauwels, R.⁶ Baba, M.⁷ Johns, D.G.⁸ De Clercq, E.⁹

21
- 0025283046
- Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro
- Yokota T, Konno K, Chonan E, Mochizuki S, Kojima K, Shigeta S, De Clercq E. Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro. Antimicrob Agents Chemother 1990;34:1326-1330.
- (1990) Antimicrob Agents Chemother , vol.34 , pp. 1326-1330
- Yokota, T.¹ Konno, K.² Chonan, E.³ Mochizuki, S.⁴ Kojima, K.⁵ Shigeta, S.⁶ De Clercq, E.⁷

22
- 0025924186
- Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis
- Yokota T, Mochizuki S, Konno K, Mori S, Shigeta S, De Clercq E. Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis. Antimicrob Agents Chemother 1991;35:394-397.
- (1991) Antimicrob Agents Chemother , vol.35 , pp. 394-397
- Yokota, T.¹ Mochizuki, S.² Konno, K.³ Mori, S.⁴ Shigeta, S.⁵ De Clercq, E.⁶

23
- 0025647251
- Therapeutic potential of phosphonylmethoxyalkylpurines and -pyrimidines as antiviral agents
- De Clercq E. Therapeutic potential of phosphonylmethoxyalkylpurines and -pyrimidines as antiviral agents. Drugs Exp Clin Res 1990;16:319-326.
- (1990) Drugs Exp Clin Res , vol.16 , pp. 319-326
- De Clercq, E.¹

24
- 0025837774
- Broad-spectrum anti-DNA virus and anti-retrovirus activity of phosphonylmethoxyalkylpurines and -pyrimidines
- De Clercq E. Broad-spectrum anti-DNA virus and anti-retrovirus activity of phosphonylmethoxyalkylpurines and -pyrimidines. Biochem Pharmacol 1991;42:963-972.
- (1991) Biochem Pharmacol , vol.42 , pp. 963-972
- De Clercq, E.¹

25
- 0037468406
- Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B
- Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-807.
- (2003) N Engl J Med , vol.348 , pp. 800-807
- Hadziyannis, S.J.¹ Tassopoulos, N.C.² Heathcote, E.J.³ Chang, T.T.⁴ Kitis, G.⁵ Rizzetto, M.⁶ Marcellin, P.⁷ Lim, S.G.⁸ Goodman, Z.⁹ Wulfsohn, M.S.¹⁰ Xiong, S.¹¹ Fry, J.¹² Brosgart, C.L.¹³

26
- 0037468421
- Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B
- Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-816.
- (2003) N Engl J Med , vol.348 , pp. 808-816
- Marcellin, P.¹ Chang, T.T.² Lim, S.G.³ Tong, M.J.⁴ Sievert, W.⁵ Shiffman, M.L.⁶ Jeffers, L.⁷ Goodman, Z.⁸ Wulfsohn, M.S.⁹ Xiong, S.¹⁰ Fry, J.¹¹ Brosgart, C.L.¹²

27
- 21244455293
- Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B
- Hadziyannis SJ, Tassopoulos NC, Heahtcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Arterburn S, Xiong S, Currie G, Brosgart CL. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352:2673-2681.
- (2005) N Engl J Med , vol.352 , pp. 2673-2681
- Hadziyannis, S.J.¹ Tassopoulos, N.C.² Heahtcote, E.J.³ Chang, T.T.⁴ Kitis, G.⁵ Rizzetto, M.⁶ Marcellin, P.⁷ Lim, S.G.⁸ Goodman, Z.⁹ Ma, J.¹⁰ Arterburn, S.¹¹ Xiong, S.¹² Currie, G.¹³ Brosgart, C.L.¹⁴

28
- 0025728272
- 9-[(2RS)-3-fluoro-2-phosphonylmethoxypropyl] derivatives of purines: A class of highly selective antiretroviral agents in vitro and in vivo
- Balzarini J, Holý A, Jindřich J, Dvořáková H, Hao Z, Snoeck R, Herdewijn P, Johns DG, De Clercq E. 9-[(2RS)-3-fluoro-2-phosphonylmethoxypropyl] derivatives of purines: A class of highly selective antiretroviral agents in vitro and in vivo. Proc Natl Acad Sci USA 1991;88:4961-4965.
- (1991) Proc Natl Acad Sci USA , vol.88 , pp. 4961-4965
- Balzarini, J.¹ Holý, A.² Jindřich, J.³ Dvořáková, H.⁴ Hao, Z.⁵ Snoeck, R.⁶ Herdewijn, P.⁷ Johns, D.G.⁸ De Clercq, E.⁹

29
- 0027534661
- Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: Potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine
- Balzarini J, Holý A, Jindřich J, Naesens L, Snoeck R, Schols D, De Clercq E. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: Potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2, 6-diaminopurine. Antimicrob Agents Chemother 1993;37:332-338.
- (1993) Antimicrob Agents Chemother , vol.37 , pp. 332-338
- Balzarini, J.¹ Holý, A.² Jindřich, J.³ Naesens, L.⁴ Snoeck, R.⁵ Schols, D.⁶ De Clercq, E.⁷

30
- 0028791836
- Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine
- Tsai CC, Follis KE, Sabo A, Beck TW, Grant RF, Bischofberger N, Benveniste RE, Black R. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995;270:1197-1199.
- (1995) Science , vol.270 , pp. 1197-1199
- Tsai, C.C.¹ Follis, K.E.² Sabo, A.³ Beck, T.W.⁴ Grant, R.F.⁵ Bischofberger, N.⁶ Benveniste, R.E.⁷ Black, R.⁸

31
- 0031916651
- Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl)-PMPA
- Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl)-PMPA. Antimicrob Agents Chemother 1998;42:612-617.
- (1998) Antimicrob Agents Chemother , vol.42 , pp. 612-617
- Robbins, B.L.¹ Srinivas, R.V.² Kim, C.³ Bischofberger, N.⁴ Fridland, A.⁵

32
- 0031863214
- Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice
- Naesens L, Bischofberger N, Augustijns P, Annaert P, Van den Mooter G, Arimilli MN, Kim CU, De Clercq E. Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice. Antimicrob Agents Chemother 1998;42:1568-1573.
- (1998) Antimicrob Agents Chemother , vol.42 , pp. 1568-1573
- Naesens, L.¹ Bischofberger, N.² Augustijns, P.³ Annaert, P.⁴ Van den Mooter, G.⁵ Arimilli, M.N.⁶ Kim, C.U.⁷ De Clercq, E.⁸

33
- 77955930318
- Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women
- CAPRISA 004 Trial Group.
- Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D; CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168-1174.
- (2010) Science , vol.329 , pp. 1168-1174
- Abdool Karim, Q.¹ Abdool Karim, S.S.² Frohlich, J.A.³ Grobler, A.C.⁴ Baxter, C.⁵ Mansoor, L.E.⁶ Kharsany, A.B.⁷ Sibeko, S.⁸ Mlisana, K.P.⁹ Omar, Z.¹⁰ Gengiah, T.N.¹¹ Maarschalk, S.¹² Arulappan, N.¹³ Mlotshwa, M.¹⁴ Morris, L.¹⁵ Taylor, D.¹⁶

34
- 80052962337
- Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa
- Williams BG, Abdool Karim SS, Karim QA, Gouws E. Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. J Acquir Immune Defic Syndr 2011;58:207-210.
- (2011) J Acquir Immune Defic Syndr , vol.58 , pp. 207-210
- Williams, B.G.¹ Abdool Karim, S.S.² Karim, Q.A.³ Gouws, E.⁴

35
- 84863832074
- Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)?
- De Clercq E. Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)? Med Res Rev 2012;32:765-785.
- (2012) Med Res Rev , vol.32 , pp. 765-785
- De Clercq, E.¹

36
- 78650549662
- Preexposure chemoprophylaxis for HIV prevention in men who have sex with men
- Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker L-G, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng J-H, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-2599.
- (2010) N Engl J Med , vol.363 , pp. 2587-2599
- Grant, R.M.¹ Lama, J.R.² Anderson, P.L.³ McMahan, V.⁴ Liu, A.Y.⁵ Vargas, L.⁶ Goicochea, P.⁷ Casapía, M.⁸ Guanira-Carranza, J.V.⁹ Ramirez-Cardich, M.E.¹⁰ Montoya-Herrera, O.¹¹ Fernández, T.¹² Veloso, V.G.¹³ Buchbinder, S.P.¹⁴ Chariyalertsak, S.¹⁵ Schechter, M.¹⁶ Bekker, L.-G.¹⁷ Mayer, K.H.¹⁸ Kallás, E.G.¹⁹ Amico, K.R.²⁰ more..

37
- 36749037438
- From adefovir to AtriplaTM via tenofovir, VireadTM and TruvadaTM
- De Clercq E. From adefovir to AtriplaTM via tenofovir, VireadTM and TruvadaTM. Future Virol 2006;1:709-715.
- (2006) Future Virol , vol.1 , pp. 709-715
- De Clercq, E.¹

38
- 30944468562
- Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV
- Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, Lu B, McColl D, Chuck S, Enejosa J, Toole JJ, Cheng AK. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354:251-260.
- (2006) N Engl J Med , vol.354 , pp. 251-260
- Gallant, J.E.¹ DeJesus, E.² Arribas, J.R.³ Pozniak, A.L.⁴ Gazzard, B.⁵ Campo, R.E.⁶ Lu, B.⁷ McColl, D.⁸ Chuck, S.⁹ Enejosa, J.¹⁰ Toole, J.J.¹¹ Cheng, A.K.¹²

39
- 33845354174
- Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: Virologic, immunologic, and morphologic changes-A 96-week analysis
- Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campo RE, Chen SS, McColl D, Enejosa J, Toole JJ, Cheng AK. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: Virologic, immunologic, and morphologic changes-A 96-week analysis. J Acquir Immune Defic Syndr 2006;43:535-540.
- (2006) J Acquir Immune Defic Syndr , vol.43 , pp. 535-540
- Pozniak, A.L.¹ Gallant, J.E.² DeJesus, E.³ Arribas, J.R.⁴ Gazzard, B.⁵ Campo, R.E.⁶ Chen, S.S.⁷ McColl, D.⁸ Enejosa, J.⁹ Toole, J.J.¹⁰ Cheng, A.K.¹¹

40
- 73349134686
- Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy
- AIDS Clinical Trials Group Study A5202 Team.
- Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Koletar SL, Johnson VA, Geiseler PJ, Daar ES; AIDS Clinical Trials Group Study A5202 Team. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009;361:2230-2240.
- (2009) N Engl J Med , vol.361 , pp. 2230-2240
- Sax, P.E.¹ Tierney, C.² Collier, A.C.³ Fischl, M.A.⁴ Mollan, K.⁵ Peeples, L.⁶ Godfrey, C.⁷ Jahed, N.C.⁸ Myers, L.⁹ Katzenstein, D.¹⁰ Farajallah, A.¹¹ Rooney, J.F.¹² Ha, B.¹³ Woodward, W.C.¹⁴ Koletar, S.L.¹⁵ Johnson, V.A.¹⁶ Geiseler, P.J.¹⁷ Daar, E.S.¹⁸

41
- 80052897871
- Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: Final results
- AIDS Clinical Trials Group Study A5202 Team.
- Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Feinberg J, Tashima K, Murphy RL, Fischl MA; AIDS Clinical Trials Group Study A5202 Team. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: Final results. J Infect Dis 2011;204:1191-1201.
- (2011) J Infect Dis , vol.204 , pp. 1191-1201
- Sax, P.E.¹ Tierney, C.² Collier, A.C.³ Daar, E.S.⁴ Mollan, K.⁵ Budhathoki, C.⁶ Godfrey, C.⁷ Jahed, N.C.⁸ Myers, L.⁹ Katzenstein, D.¹⁰ Farajallah, A.¹¹ Rooney, J.F.¹² Ha, B.¹³ Woodward, W.C.¹⁴ Feinberg, J.¹⁵ Tashima, K.¹⁶ Murphy, R.L.¹⁷ Fischl, M.A.¹⁸

42
- 70349682997
- Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934
- Study 934 Team.
- Margot NA, Enejosa J, Cheng AK, Miller MD, McColl DJ; Study 934 Team. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934. J Acquir Immune Defic Syndr 2009;52:209-221.
- (2009) J Acquir Immune Defic Syndr , vol.52 , pp. 209-221
- Margot, N.A.¹ Enejosa, J.² Cheng, A.K.³ Miller, M.D.⁴ McColl, D.J.⁵

43
- 79960358849
- Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): A phase 3, randomised, non-inferiority trial
- THRIVE Study Group.
- Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, Wu H, Zorrilla C, Crauwels H, Rimsky LT, Vanveggel S, Boven K; THRIVE Study Group. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): A phase 3, randomised, non-inferiority trial. Lancet 2011;378:229-237.
- (2011) Lancet , vol.378 , pp. 229-237
- Cohen, C.J.¹ Andrade-Villanueva, J.² Clotet, B.³ Fourie, J.⁴ Johnson, M.A.⁵ Ruxrungtham, K.⁶ Wu, H.⁷ Zorrilla, C.⁸ Crauwels, H.⁹ Rimsky, L.T.¹⁰ Vanveggel, S.¹¹ Boven, K.¹²

44
- 79960381844
- Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial
- ECHO Study Group.
- Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, Supparatpinyo K, Walmsley S, Crauwels H, Rimsky LT, Vanveggel S, Boven K; ECHO Study Group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial. Lancet 2011;378:238-246.
- (2011) Lancet , vol.378 , pp. 238-246
- Molina, J.M.¹ Cahn, P.² Grinsztejn, B.³ Lazzarin, A.⁴ Mills, A.⁵ Saag, M.⁶ Supparatpinyo, K.⁷ Walmsley, S.⁸ Crauwels, H.⁹ Rimsky, L.T.¹⁰ Vanveggel, S.¹¹ Boven, K.¹²

45
- 84885913235
- http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle_Print&ID=1759088&highlight=

46
- 84861977399
- Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era
- De Clercq E. Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era. Biochem Pharmacol 2012;84:241-248.
- (2012) Biochem Pharmacol , vol.84 , pp. 241-248
- De Clercq, E.¹

47
- 84885931430
- http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=1759099&highlight=

48
- 84863816714
- Elvitegravir/cobicistat/emtricitabine/tenofovir (Quad) has non-inferior efficacy and favorable safety compared to efavirenz/emtricitabine/tenofovir in treatment-naïve HIV-1+ subjects
- th Conference on Retroviruses and Opportunistic Infections, Washington, Seattle, 5-8 March 2012. Abstracts, 101.
- th Conference on Retroviruses and Opportunistic Infections, Washington, Seattle, 5-8 March 2012. Abstracts, # 101.
- Sax, P.¹ DeJesus, E.² Mills, A.³ Zolopa, A.⁴ Cohen, C.⁵ Wohl, D.⁶ Gallant, J.⁷ Liu, H.⁸ Quirk, E.⁹ Kearney, B.¹⁰

49
- 79953735724
- Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection
- Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, Chuck SL, Yale K, Liu HC, Warren DR, Ramanathan S, Kearney BP. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 2011;25:F7-F12.
- (2011) AIDS , vol.25
- Cohen, C.¹ Elion, R.² Ruane, P.³ Shamblaw, D.⁴ DeJesus, E.⁵ Rashbaum, B.⁶ Chuck, S.L.⁷ Yale, K.⁸ Liu, H.C.⁹ Warren, D.R.¹⁰ Ramanathan, S.¹¹ Kearney, B.P.¹²

50
- 84875814791
- Week 48 results of an ongoing global phase 3 study comparing elvitegravir/cobicistat/emtricitabine/tenofovir (Quad) with atazanavir/ritonavir plus emtricitabine/tenofovir in treatment-naïve HIV-1+ subjects showing efficacy, safety, and pharmacokinetics
- th Conference on Retroviruses and Opportunistic Infections, Washington, Seattle, 5-8 March 2012. Abstracts, 627.
- th Conference on Retroviruses and Opportunistic Infections, Washington, Seattle, 5-8 March 2012. Abstracts, # 627.
- DeJesus, E.¹ Rockstroh, J.² Henry, K.³ Molina, J.-M.⁴ Gathe, J.⁵ Ramanathan, S.⁶ Wei, X.⁷ Szwarcberg, J.⁸ Jandourek, A.⁹ Cheng, A.¹⁰

51
- 79953735724
- Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection
- Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, Chuck SL, Yale K, Liu HC, Warren DR, Ramanathan S, Kearney BP. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 2011;25:1881-1886.
- (2011) AIDS , vol.25 , pp. 1881-1886
- Cohen, C.¹ Elion, R.² Ruane, P.³ Shamblaw, D.⁴ DeJesus, E.⁵ Rashbaum, B.⁶ Chuck, S.L.⁷ Yale, K.⁸ Liu, H.C.⁹ Warren, D.R.¹⁰ Ramanathan, S.¹¹ Kearney, B.P.¹²

52
- 84885913626
- http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=1752101&highlight=

53
- 18244398917
- Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue
- Lee WA, He GX, Eisenberg E, Cihlar T, Swaminathan S, Mulato A, Cundy KC. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother 2005;49:1898-1906.
- (2005) Antimicrob Agents Chemother , vol.49 , pp. 1898-1906
- Lee, W.A.¹ He, G.X.² Eisenberg, E.³ Cihlar, T.⁴ Swaminathan, S.⁵ Mulato, A.⁶ Cundy, K.C.⁷

54
- 33846690778
- Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131
- Birkus G, Wang R, Liu X, Kutty N, MacArthur H, Cihlar T, Gibbs C, Swaminathan S, Lee W, McDermott M. Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131. Antimicrob Agents Chemother 2007;51:543-550.
- (2007) Antimicrob Agents Chemother , vol.51 , pp. 543-550
- Birkus, G.¹ Wang, R.² Liu, X.³ Kutty, N.⁴ MacArthur, H.⁵ Cihlar, T.⁶ Gibbs, C.⁷ Swaminathan, S.⁸ Lee, W.⁹ McDermott, M.¹⁰

55
- 45749091322
- Activation of 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases
- Birkus G, Kutty N, He GX, Mulato A, Lee W, McDermott M, Cihlar T. Activation of 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases. Mol Pharmacol 2008;74:92-100.
- (2008) Mol Pharmacol , vol.74 , pp. 92-100
- Birkus, G.¹ Kutty, N.² He, G.X.³ Mulato, A.⁴ Lee, W.⁵ McDermott, M.⁶ Cihlar, T.⁷

56
- 84885946806
- http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle_Print&ID=1630785&highlight=

57
- 84885915510
- http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle_Print&ID=1652096&highlight=

58
- 67349157073
- Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art
- Hostetler KY. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res 2009;82:A84-A98.
- (2009) Antiviral Res , vol.82
- Hostetler, K.Y.¹

59
- 34948857943
- Evaluation of hexadecyloxypropyl-9-R-[2-(phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections
- Painter GR, Almond MR, Trost LC, Lampert BM, Neyts J, De Clercq E, Korba BE, Aldern KA, Beadle JR, Hostetler KY. Evaluation of hexadecyloxypropyl-9-R-[2-(phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections. Antimicrob Agents Chemother 2007;51:3505-3509.
- (2007) Antimicrob Agents Chemother , vol.51 , pp. 3505-3509
- Painter, G.R.¹ Almond, M.R.² Trost, L.C.³ Lampert, B.M.⁴ Neyts, J.⁵ De Clercq, E.⁶ Korba, B.E.⁷ Aldern, K.A.⁸ Beadle, J.R.⁹ Hostetler, K.Y.¹⁰

60
- 77953796821
- Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV
- Lanier ER, Ptak RG, Lampert BM, Keilholz L, Hartman T, Buckheit RW, Jr, Mankowski MK, Osterling MC, Almond MR, Painter GR. Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. Antimicrob Agents Chemother 2010;54:2901-2909.
- (2010) Antimicrob Agents Chemother , vol.54 , pp. 2901-2909
- Lanier, E.R.¹ Ptak, R.G.² Lampert, B.M.³ Keilholz, L.⁴ Hartman, T.⁵ Buckheit Jr, R.W.⁶ Mankowski, M.K.⁷ Osterling, M.C.⁸ Almond, M.R.⁹ Painter, G.R.¹⁰

61
- 57349132991
- Mechanism of antiviral drug resistance of vaccinia virus: Identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs
- Gammon DB, Snoeck R, Fiten P, Krečmerová M, Holý A, De Clercq E, Opdenakker G, Evans DH, Andrei G. Mechanism of antiviral drug resistance of vaccinia virus: Identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs. J Virol 2008;82:12520-12534.
- (2008) J Virol , vol.82 , pp. 12520-12534
- Gammon, D.B.¹ Snoeck, R.² Fiten, P.³ Krečmerová, M.⁴ Holý, A.⁵ De Clercq, E.⁶ Opdenakker, G.⁷ Evans, D.H.⁸ Andrei, G.⁹

62
- 77957900154
- Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as anti-poxvirus agents
- Krečmerová M, Holý A, Andrei G, Pomeisl K, Tichý T, Břehová P, Masojídková M, Dračínský M, Pohl R, Laflamme G, Naesens L, Hui H, Cihlar T, Neyts J, De Clercq E, Balzarini J, Snoeck R. Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2, 6-diaminopurine (HPMPDAP) as anti-poxvirus agents. J Med Chem 2010;53:6825-6837.
- (2010) J Med Chem , vol.53 , pp. 6825-6837
- Krečmerová, M.¹ Holý, A.² Andrei, G.³ Pomeisl, K.⁴ Tichý, T.⁵ Břehová, P.⁶ Masojídková, M.⁷ Dračínský, M.⁸ Pohl, R.⁹ Laflamme, G.¹⁰ Naesens, L.¹¹ Hui, H.¹² Cihlar, T.¹³ Neyts, J.¹⁴ De Clercq, E.¹⁵ Balzarini, J.¹⁶ Snoeck, R.¹⁷

63
- 0033564975
- 6-cyclopropyl-PMEDAP: A novel derivative of 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) with distinct metabolic, antiproliferative, and differentiation-inducing properties
- 6-cyclopropyl-PMEDAP: A novel derivative of 9-(2-phosphonylmethoxyethyl)-2, 6-diaminopurine (PMEDAP) with distinct metabolic, antiproliferative, and differentiation-inducing properties. Biochem Pharmacol 1999;58:311-323.
- (1999) Biochem Pharmacol , vol.58 , pp. 311-323
- Hatse, S.¹ Naesens, L.² De Clercq, E.³ Balzarini, J.⁴

64
- 0033257908
- 6-cyclopropyl-2,6-diaminopurine: A novel prodrug of 9-(2-phosphonylmethoxyethyl)guanine with improved antitumor efficacy and selectivity in choriocarcinoma-bearing rats
- 6-cyclopropyl-2, 6-diaminopurine: A novel prodrug of 9-(2-phosphonylmethoxyethyl)guanine with improved antitumor efficacy and selectivity in choriocarcinoma-bearing rats. Oncol Res 1999;11:195-203.
- (1999) Oncol Res , vol.11 , pp. 195-203
- Naesens, L.¹ Hatse, S.² Segers, C.³ Verbeken, E.⁴ De Clercq, E.⁵ Waer, M.⁶ Balzarini, J.⁷

65
- 83555174468
- Enhanced topical and transdermal delivery of antineoplastic and antiviral acyclic nucleoside phosphonate cPr-PMEDAP
- Vávrová K, Kovaříková P, Skolová B, Líbalová M, Roh J, Cáp R, Holý A, Hrabálek A. Enhanced topical and transdermal delivery of antineoplastic and antiviral acyclic nucleoside phosphonate cPr-PMEDAP. Pharm Res 2011;28:3105-3115.
- (2011) Pharm Res , vol.28 , pp. 3105-3115
- Vávrová, K.¹ Kovaříková, P.² Skolová, B.³ Líbalová, M.⁴ Roh, J.⁵ Cáp, R.⁶ Holý, A.⁷ Hrabálek, A.⁸

66
- 33645113651
- 6-substituted purine acyclic nucleoside phosphonates
- 6-substituted purine acyclic nucleoside phosphonates. Biochem Pharmacol 2006;71:1370-1376.
- (2006) Biochem Pharmacol , vol.71 , pp. 1370-1376
- Schinkmanová, M.¹ Votruba, I.² Holý, A.³

67
- 67650003697
- GS-9191 is a novel topical prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine with antiproliferative activity and possible utility in the treatment of human papillomavirus lesions
- Wolfgang GH, Shibata R, Wang J, Ray AS, Wu S, Doerrfler E, Reiser H, Lee WA, Birkus G, Christensen ND, Andrei G, Snoeck R. GS-9191 is a novel topical prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine with antiproliferative activity and possible utility in the treatment of human papillomavirus lesions. Antimicrob Agents Chemother 2009;53:2777-2784.
- (2009) Antimicrob Agents Chemother , vol.53 , pp. 2777-2784
- Wolfgang, G.H.¹ Shibata, R.² Wang, J.³ Ray, A.S.⁴ Wu, S.⁵ Doerrfler, E.⁶ Reiser, H.⁷ Lee, W.A.⁸ Birkus, G.⁹ Christensen, N.D.¹⁰ Andrei, G.¹¹ Snoeck, R.¹²

68
- 52049093225
- GS-9219-A novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma
- Reiser H, Wang J, Chong L, Watkins WJ, Ray AS, Shibata R, Birkus G, Cihlar T, Wu S, Li B, Liu X, Henne IN, Wolfgang GH, Desai M, Rhodes GR, Fridland A, Lee WA, Plunkett W, Vail D, Thamm DH, Jeraj R, Tumas DB. GS-9219-A novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma. Clin Cancer Res 2008;14:2824-2832.
- (2008) Clin Cancer Res , vol.14 , pp. 2824-2832
- Reiser, H.¹ Wang, J.² Chong, L.³ Watkins, W.J.⁴ Ray, A.S.⁵ Shibata, R.⁶ Birkus, G.⁷ Cihlar, T.⁸ Wu, S.⁹ Li, B.¹⁰ Liu, X.¹¹ Henne, I.N.¹² Wolfgang, G.H.¹³ Desai, M.¹⁴ Rhodes, G.R.¹⁵ Fridland, A.¹⁶ Lee, W.A.¹⁷ Plunkett, W.¹⁸ Vail, D.¹⁹ Thamm, D.H.²⁰ Jeraj, R.²¹ Tumas, D.B.²² more..

69
- 80052929778
- A novel and efficient one-pot synthesis of symmetrical diamide (bis-amidate) prodrugs of acyclic nucleoside phosphonates and evaluation of their biological activities
- Jansa P, Baszczyňski O, Dračínský M, Votruba I, Zídek Z, Bahador G, Stepan G, Cihlar T, Mackman R, Holý A, Janeba Z. A novel and efficient one-pot synthesis of symmetrical diamide (bis-amidate) prodrugs of acyclic nucleoside phosphonates and evaluation of their biological activities. Eur J Med Chem 2011;46:3748-3754.
- (2011) Eur J Med Chem , vol.46 , pp. 3748-3754
- Jansa, P.¹ Baszczyňski, O.² Dračínský, M.³ Votruba, I.⁴ Zídek, Z.⁵ Bahador, G.⁶ Stepan, G.⁷ Cihlar, T.⁸ Mackman, R.⁹ Holý, A.¹⁰ Janeba, Z.¹¹

70
- 0037171739
- 6-[2-(phosphonomethoxy)alkoxy]pyrimidines with antiviral activity
- Holý A, Votruba I, Masojídková M, Andrei G, Snoeck R, Naesens L, De Clercq E, Balzarini J. 6-[2-(phosphonomethoxy)alkoxy]pyrimidines with antiviral activity. J Med Chem 2002;45:1918-1929.
- (2002) J Med Chem , vol.45 , pp. 1918-1929
- Holý, A.¹ Votruba, I.² Masojídková, M.³ Andrei, G.⁴ Snoeck, R.⁵ Naesens, L.⁶ De Clercq, E.⁷ Balzarini, J.⁸

71
- 0242299576
- 5-substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity
- Hocková D, Holý A, Masojídková M, Andrei G, Snoeck R, De Clercq E, Balzarini J. 5-substituted-2, 4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity. J Med Chem 2003;46:5064-5073.
- (2003) J Med Chem , vol.46 , pp. 5064-5073
- Hocková, D.¹ Holý, A.² Masojídková, M.³ Andrei, G.⁴ Snoeck, R.⁵ De Clercq, E.⁶ Balzarini, J.⁷

72
- 25144470707
- Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines
- De Clercq E, Andrei G, Balzarini J, Leyssen P, Naesens L, Neyts J, Pannecouque C, Snoeck R, Ying C, Hocková D, Holý A. Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2, 4-diaminopyrimidines. Nucleosides Nucleotides Nucleic Acids 2005;24:331-341.
- (2005) Nucleosides Nucleotides Nucleic Acids , vol.24 , pp. 331-341
- De Clercq, E.¹ Andrei, G.² Balzarini, J.³ Leyssen, P.⁴ Naesens, L.⁵ Neyts, J.⁶ Pannecouque, C.⁷ Snoeck, R.⁸ Ying, C.⁹ Hocková, D.¹⁰ Holý, A.¹¹

73
- 14744267233
- Antiadenovirus activities of several classes of nucleoside and nucleotide analogues
- Naesens L, Lenaerts L, Andrei G, Snoeck R, Van Beers D, Holý A, Balzarini J, De Clercq E. Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob Agents Chemother 2005;49:1010-1016.
- (2005) Antimicrob Agents Chemother , vol.49 , pp. 1010-1016
- Naesens, L.¹ Lenaerts, L.² Andrei, G.³ Snoeck, R.⁴ Van Beers, D.⁵ Holý, A.⁶ Balzarini, J.⁷ De Clercq, E.⁸

74
- 0035984791
- Antiretrovirus activity of a novel class of acyclic pyrimidine nucleoside phosphonates
- Balzarini J, Pannecouque C, De Clercq E, Aquaro S, Perno CF, Egberink H, Holý A. Antiretrovirus activity of a novel class of acyclic pyrimidine nucleoside phosphonates. Antimicrob Agents Chemother 2002;46:2185-2193.
- (2002) Antimicrob Agents Chemother , vol.46 , pp. 2185-2193
- Balzarini, J.¹ Pannecouque, C.² De Clercq, E.³ Aquaro, S.⁴ Perno, C.F.⁵ Egberink, H.⁶ Holý, A.⁷

75
- 33845901770
- Pronounced in vitro and in vivo antiretroviral activity of 5-substituted 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy] pyrimidines
- Balzarini J, Schols D, Van Laethem K, De Clercq E, Hocková D, Masojídková M, Holý A. Pronounced in vitro and in vivo antiretroviral activity of 5-substituted 2, 4-diamino-6-[2-(phosphonomethoxy)ethoxy] pyrimidines. J Antimicrob Chemother 2007;59:80-86.
- (2007) J Antimicrob Chemother , vol.59 , pp. 80-86
- Balzarini, J.¹ Schols, D.² Van Laethem, K.³ De Clercq, E.⁴ Hocková, D.⁵ Masojídková, M.⁶ Holý, A.⁷

76
- 14744274964
- Novel acyclic nucleoside phosphonate analogues with potent anti-hepatitis B virus activities
- Ying C, Holý A, Hocková D, Havlas Z, De Clercq E, Neyts J. Novel acyclic nucleoside phosphonate analogues with potent anti-hepatitis B virus activities. Antimicrob Agents Chemother 2005;49:1177-1180.
- (2005) Antimicrob Agents Chemother , vol.49 , pp. 1177-1180
- Ying, C.¹ Holý, A.² Hocková, D.³ Havlas, Z.⁴ De Clercq, E.⁵ Neyts, J.⁶

77
- 2542428468
- Synthesis and antiviral activity of 2,4-diamino-5-cyano-6-[2-(phosphonomethoxy)ethoxy]pyrimidine and related compounds
- Hocková D, Holý A, Masojídková M, Andrei G, Snoeck R, De Clercq E, Balzarini J. Synthesis and antiviral activity of 2, 4-diamino-5-cyano-6-[2-(phosphonomethoxy)ethoxy]pyrimidine and related compounds. Bioorg Med Chem 2004;12:3197-3202.
- (2004) Bioorg Med Chem , vol.12 , pp. 3197-3202
- Hocková, D.¹ Holý, A.² Masojídková, M.³ Andrei, G.⁴ Snoeck, R.⁵ De Clercq, E.⁶ Balzarini, J.⁷

78
- 77951244983
- The acyclic 2,4-diaminopyrimidine nucleoside phosphonate acts as a purine mimetic in HIV-1 reverse transcriptase DNA polymerization
- Herman BD, Votruba I, Holý A, Sluis-Cremer N, Balzarini J. The acyclic 2, 4-diaminopyrimidine nucleoside phosphonate acts as a purine mimetic in HIV-1 reverse transcriptase DNA polymerization. J Biol Chem 2010;285:12101-12108.
- (2010) J Biol Chem , vol.285 , pp. 12101-12108
- Herman, B.D.¹ Votruba, I.² Holý, A.³ Sluis-Cremer, N.⁴ Balzarini, J.⁵

79
- 33847772580
- Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds
- Krečmerová M, Holý A, Pískala A, Masojídková M, Andrei G, Naesens L, Neyts J, Balzarini J, De Clercq E, Snoeck R. Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds. J Med Chem 2007;50:1069-1077.
- (2007) J Med Chem , vol.50 , pp. 1069-1077
- Krečmerová, M.¹ Holý, A.² Pískala, A.³ Masojídková, M.⁴ Andrei, G.⁵ Naesens, L.⁶ Neyts, J.⁷ Balzarini, J.⁸ De Clercq, E.⁹ Snoeck, R.¹⁰

80
- 36148947861
- Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: Synthesis and antiviral activity
- Krečmerová M, Holý A, Pohl R, Masojídková M, Andrei G, Naesens L, Neyts J, Balzarini J, De Clercq E, Snoeck R. Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: Synthesis and antiviral activity. J Med Chem 2007;50:5765-5772.
- (2007) J Med Chem , vol.50 , pp. 5765-5772
- Krečmerová, M.¹ Holý, A.² Pohl, R.³ Masojídková, M.⁴ Andrei, G.⁵ Naesens, L.⁶ Neyts, J.⁷ Balzarini, J.⁸ De Clercq, E.⁹ Snoeck, R.¹⁰

81
- 52949088625
- Intracellular metabolism of the new antiviral compound 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine
- Naesens L, Andrei G, Votruba I, Krečmerová M, Holý A, Neyts J, De Clercq E, Snoeck R. Intracellular metabolism of the new antiviral compound 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine. Biochem Pharmacol 2008;76:997-1005.
- (2008) Biochem Pharmacol , vol.76 , pp. 997-1005
- Naesens, L.¹ Andrei, G.² Votruba, I.³ Krečmerová, M.⁴ Holý, A.⁵ Neyts, J.⁶ De Clercq, E.⁷ Snoeck, R.⁸

82
- 34250188092
- Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains
- Lebeau I, Andrei G, Krečmerová M, De Clercq E, Holý A, Snoeck R. Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains. Antimicrob Agents Chemother 2007;51:2268-2273.
- (2007) Antimicrob Agents Chemother , vol.51 , pp. 2268-2273
- Lebeau, I.¹ Andrei, G.² Krečmerová, M.³ De Clercq, E.⁴ Holý, A.⁵ Snoeck, R.⁶

83
- 36749040780
- Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models
- Duraffour S, Snoeck R, Krečmerová M, van Den Oord J, De Vos R, Holý A, Crance JM, Garin D, De Clercq E, Andrei G. Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models. Antimicrob Agents Chemother 2007;51:4410-4419.
- (2007) Antimicrob Agents Chemother , vol.51 , pp. 4410-4419
- Duraffour, S.¹ Snoeck, R.² Krečmerová, M.³ van Den Oord, J.⁴ De Vos, R.⁵ Holý, A.⁶ Crance, J.M.⁷ Garin, D.⁸ De Clercq, E.⁹ Andrei, G.¹⁰

84
- 67650745021
- Inhibition of hypoxanthine-guanine phosphoribosyltransferase by acyclic nucleoside phosphonates: A new class of antimalarial therapeutics
- Keough DT, Hocková D, Holý A, Naesens LM, Skinner-Adams TS, Jersey J, Guddat LW. Inhibition of hypoxanthine-guanine phosphoribosyltransferase by acyclic nucleoside phosphonates: A new class of antimalarial therapeutics. J Med Chem 2009;52:4391-4399.
- (2009) J Med Chem , vol.52 , pp. 4391-4399
- Keough, D.T.¹ Hocková, D.² Holý, A.³ Naesens, L.M.⁴ Skinner-Adams, T.S.⁵ Jersey, J.⁶ Guddat, L.W.⁷

85
- 68649085928
- Synthesis of branched 9-[2-(2-phosphonoethoxy)ethyl]purines as a new class of acyclic nucleoside phosphonates which inhibit Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase
- Hocková D, Holý A, Masojídková M, Keough DT, de Jersey J, Guddat LW. Synthesis of branched 9-[2-(2-phosphonoethoxy)ethyl]purines as a new class of acyclic nucleoside phosphonates which inhibit Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase. Bioorg Med Chem 2009;17:6218-6232.
- (2009) Bioorg Med Chem , vol.17 , pp. 6218-6232
- Hocková, D.¹ Holý, A.² Masojídková, M.³ Keough, D.T.⁴ de Jersey, J.⁵ Guddat, L.W.⁶

86
- 84855784224
- Synthesis of 9-phosphonoalkyl and 9-phosphonoalkoxyalkyl purines: Evaluation of their ability to act as inhibitors of Plasmodium falciparum, Plasmodium vivax and human hypoxanthine-guanine-(xanthine) phosphoribosyltransferases
- Česnek M, Hocková D, Holý A, Dračínský M, Baszczyňski O, Jersey Jd, Keough DT, Guddat LW. Synthesis of 9-phosphonoalkyl and 9-phosphonoalkoxyalkyl purines: Evaluation of their ability to act as inhibitors of Plasmodium falciparum, Plasmodium vivax and human hypoxanthine-guanine-(xanthine) phosphoribosyltransferases. Bioorg Med Chem 2012;20:1076-1089.
- (2012) Bioorg Med Chem , vol.20 , pp. 1076-1089
- Česnek, M.¹ Hocková, D.² Holý, A.³ Dračínský, M.⁴ Baszczyňski, O.⁵ Jersey, J.⁶ Keough, D.T.⁷ Guddat, L.W.⁸

87
- 77954761602
- Plasmodium vivax hypoxanthine-guanine phosphoribosyltransferase: A target for anti-malarial chemotherapy
- Keough DT, Hocková D, Krečmerová M, Česnek M, Holý A, Naesens L, Brereton IM, Winzor DJ, de Jersey J, Guddat LW. Plasmodium vivax hypoxanthine-guanine phosphoribosyltransferase: A target for anti-malarial chemotherapy. Mol Biochem Parasitol 2010;173:165-169.
- (2010) Mol Biochem Parasitol , vol.173 , pp. 165-169
- Keough, D.T.¹ Hocková, D.² Krečmerová, M.³ Česnek, M.⁴ Holý, A.⁵ Naesens, L.⁶ Brereton, I.M.⁷ Winzor, D.J.⁸ de Jersey, J.⁹ Guddat, L.W.¹⁰

88
- 80051681004
- 6-oxopurine phosphoribosyltransferase: A target for the development of antimalarial drugs
- de Jersey J, Holý A, Hocková D, Naesens L, Keough DT, Guddat LW. 6-oxopurine phosphoribosyltransferase: A target for the development of antimalarial drugs. Curr Top Med Chem 2011;11:2085-2102.
- (2011) Curr Top Med Chem , vol.11 , pp. 2085-2102
- de Jersey, J.¹ Holý, A.² Hocková, D.³ Naesens, L.⁴ Keough, D.T.⁵ Guddat, L.W.⁶

89
- 84856233989
- Synthesis of purine N9-[2-hydroxy-3-O-(phosphonomethoxy)propyl] derivatives and their side-chain modified analogs as potential antimalarial agents
- Krečmerová M, Dračínský M, Hocková D, Holý A, Keough DT, Guddat LW. Synthesis of purine N9-[2-hydroxy-3-O-(phosphonomethoxy)propyl] derivatives and their side-chain modified analogs as potential antimalarial agents. Bioorg Med Chem 2012;20:1222-1230.
- (2012) Bioorg Med Chem , vol.20 , pp. 1222-1230
- Krečmerová, M.¹ Dračínský, M.² Hocková, D.³ Holý, A.⁴ Keough, D.T.⁵ Guddat, L.W.⁶

90
- 84863826337
- Synthesis of novel N-branched acyclic nucleoside phosphonates as potent and selective inhibitors of human, Plasmodium falciparum and Plasmodium vivax 6-oxopurine phosphoribosyltransferases
- Hocková D, Keough DT, Janeba Z, Wang TH, de Jersey J, Guddat LW. Synthesis of novel N-branched acyclic nucleoside phosphonates as potent and selective inhibitors of human, Plasmodium falciparum and Plasmodium vivax 6-oxopurine phosphoribosyltransferases. J Med Chem 2012;55:6209-6223.
- (2012) J Med Chem , vol.55 , pp. 6209-6223
- Hocková, D.¹ Keough, D.T.² Janeba, Z.³ Wang, T.H.⁴ de Jersey, J.⁵ Guddat, L.W.⁶

91
- 0043245952
- The acyclic nucleoside phosphonate analogues, adefovir, tenofovir and PMEDAP, efficiently eliminate banana streak virus from banana (Musa spp.)
- Helliot B, Panis B, Frison E, De Clercq E, Swennen R, Lepoivre P, Neyts J. The acyclic nucleoside phosphonate analogues, adefovir, tenofovir and PMEDAP, efficiently eliminate banana streak virus from banana (Musa spp.). Antiviral Res 2003;59:121-126.
- (2003) Antiviral Res , vol.59 , pp. 121-126
- Helliot, B.¹ Panis, B.² Frison, E.³ De Clercq, E.⁴ Swennen, R.⁵ Lepoivre, P.⁶ Neyts, J.⁷

92
- 78649451624
- New in vitro method for evaluating antiviral activity of acyclic nucleoside phosphonates against plant viruses
- Špak J, Holý A, Pavingerová D, Votruba I, Špaková V, Petrzik K. New in vitro method for evaluating antiviral activity of acyclic nucleoside phosphonates against plant viruses. Antiviral Res 2010;88:296-303.
- (2010) Antiviral Res , vol.88 , pp. 296-303
- Špak, J.¹ Holý, A.² Pavingerová, D.³ Votruba, I.⁴ Špaková, V.⁵ Petrzik, K.⁶

93
- 80054861983
- Antiviral activity of tenofovir against Cauliflower mosaic virus and its metabolism in Brassica pekinensis plants
- Špak J, Votruba I, Pavingerová D, Holý A, Špaková V, Petrzik K. Antiviral activity of tenofovir against Cauliflower mosaic virus and its metabolism in Brassica pekinensis plants. Antiviral Res 2011;92:378-381.
- (2011) Antiviral Res , vol.92 , pp. 378-381
- Špak, J.¹ Votruba, I.² Pavingerová, D.³ Holý, A.⁴ Špaková, V.⁵ Petrzik, K.⁶

94
- 27844455955
- Acyclic nucleoside phosphonates: A key class of antiviral drugs
- De Clercq E, Holý A. Acyclic nucleoside phosphonates: A key class of antiviral drugs. Nat Rev Drug Discov 2005;4:928-940.
- (2005) Nat Rev Drug Discov , vol.4 , pp. 928-940
- De Clercq, E.¹ Holý, A.²

95
- 79958161571
- The clinical potential of the acyclic (and cyclic) nucleoside phosphonates: The magic of the phosphonate bond
- De Clercq E. The clinical potential of the acyclic (and cyclic) nucleoside phosphonates: The magic of the phosphonate bond. Biochem Pharmacol 2011;82:99-109.
- (2011) Biochem Pharmacol , vol.82 , pp. 99-109
- De Clercq, E.¹

96
- 0345138983
- Phosphonomethoxyalkyl analogs of nucleotides
- Holý A. Phosphonomethoxyalkyl analogs of nucleotides. Curr Pharm Des 2003;9:2567-2592.
- (2003) Curr Pharm Des , vol.9 , pp. 2567-2592
- Holý, A.¹

97
- 34247275133
- The acyclic nucleoside phosphonates from inception to clinical use: Historical perspective
- De Clercq E. The acyclic nucleoside phosphonates from inception to clinical use: Historical perspective. Antiviral Res 2007;75:1-3.
- (2007) Antiviral Res , vol.75 , pp. 1-3
- De Clercq, E.¹

98
- 0030708683
- In search of a selective antiviral chemotherapy
- De Clercq E. In search of a selective antiviral chemotherapy. Clin Microbiol Rev 1977;10:674-693.
- (1977) Clin Microbiol Rev , vol.10 , pp. 674-693
- De Clercq, E.¹

99
- 84863113618
- Medicinal chemistry of nucleoside phosphonate prodrugs for antiviral therapy
- Pertusati F, Serpi M, McGuigan C. Medicinal chemistry of nucleoside phosphonate prodrugs for antiviral therapy. Antivir Chem Chemother 2012;22:181-203.
- (2012) Antivir Chem Chemother , vol.22 , pp. 181-203
- Pertusati, F.¹ Serpi, M.² McGuigan, C.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.